Renewal season is forcing a decision most benefits committees have been deferring for three years. Here is what the data actually supports.
Every employer we talk to is having some version of the same meeting. Someone pulls up the pharmacy report, points at the line where GLP-1 coverage sits, and asks the question nobody wants to answer out loud: can we keep paying for this?
It is a fair question. It is also the wrong first question. Before you decide whether to keep, cut, or restructure GLP-1 coverage for 2027, you need to know what you are actually looking at, because the numbers circulating in the market right now describe wildly different employers, and using the wrong benchmark is how good companies make expensive decisions.
Why GLP-1 Coverage Became the Hardest Line Item on the Renewal
GLP-1 medications did something unusual. They moved from a narrow diabetes therapy to a broadly demanded benefit in roughly four years, and they did it faster than plan design could adapt. Most employers added GLP-1 coverage for weight management when utilization was low and the clinical story was compelling. Then utilization caught up.
The International Foundation of Employee Benefit Plans found that GLP-1 drugs now account for 11.4 percent of total annual claims among employers that cover them, up from 6.9 percent in 2023. Roughly one in nine dollars of pharmacy spend is going to a single drug class. No other category moved that fast.
Business Group on Health found the pressure showing up in coverage intent. Nearly eight in ten large employers say GLP-1s are driving up their health care costs, and among companies that currently cover the drugs for weight management, only 72 percent expect to continue that coverage in 2027. Ten percent expect to drop it. Another 18 percent have not decided.
That undecided group is the interesting one. Those are employers who know the status quo is not working and have not yet found a version of GLP-1 coverage they can defend.
11.4%Share of total annual claims going to GLP-1 drugs among employers that cover them, up from 6.9 percent in 2023 (IFEBP, 2026).
What the 2026 Data Says About GLP-1 Coverage
Coverage rates depend entirely on who is being counted
You have probably seen three different numbers for how many employers offer GLP-1 coverage for weight loss. All three are correct. They just describe different companies.
| Source | Population measured | Weight-loss coverage |
|---|---|---|
| KFF Employer Health Benefits Survey | Firms with 200 or more workers | 19 percent |
| KFF Employer Health Benefits Survey | Firms with 5,000 or more workers | 43 percent |
| IFEBP Pulse Survey | US corporate plan sponsors | 36 percent (diabetes and weight loss) |
| Business Group on Health | Very large, benefits-advised employers | 67 percent |
KFF’s data shows the split clearly: 19 percent of firms with 200 or more workers covered GLP-1 agonists primarily for weight loss, compared with 43 percent of firms with 5,000 or more workers. If you employ 300 people and someone tells you “most employers cover these,” they are quoting a jumbo-employer number at you.
Pick the benchmark that matches your size, your funding arrangement, and your industry. Anything else is a talent-market argument dressed up as a data point.
Coverage is not one decision anymore
The yes-or-no framing has largely collapsed. IFEBP found 60 percent of employers cover GLP-1s for diabetes only, 36 percent cover both diabetes and weight management, and 45 percent cover them for other approved indications such as obstructive sleep apnea and cardiovascular risk reduction. The same plan routinely says yes for one indication and no for another.
That matters for how you frame GLP-1 coverage internally. You are not voting the drug class up or down. You are drawing a line around indications, eligibility, and duration, and then defending where you drew it.
Medicare Just Changed the Comparison Set
Something shifted in 2026 that changes the conversation your employees are having, even if it does not change your plan directly.
CMS launched the Medicare GLP-1 Bridge on July 1, 2026, giving eligible Part D beneficiaries access to certain weight-management GLP-1s for $50 per month. The program runs through December 31, 2027. Under it, participating manufacturers supply the drugs at a negotiated net price of $245 per monthly supply.
Separately, Novo Nordisk announced a unified US list price of $675 per month for Wegovy, Ozempic, and Rybelsus beginning January 1, 2027. Oral GLP-1s are now on the market too, which most large employers expect to increase demand rather than reduce it.
A federal program is buying the same molecule for $245 a month. Your employees will find that number, and they will ask you about it.
Here is the practical implication. The floor on what these drugs can cost has been publicly established. When your plan pays several times that, the gap is no longer invisible. It becomes a transparency question, and transparency questions are exactly where the old broker model tends to go quiet.
Three Numbers That Should Drive Your GLP-1 Coverage Decision
1. Your eligible population, not your current utilizers
Most employers model GLP-1 coverage off who is filling scripts today. That understates the exposure badly. A meaningful share of any adult population meets clinical criteria for these medications, and demand has consistently outrun forecasts. Model the population that qualifies under whatever eligibility rules you set, then apply a realistic uptake curve. If your projection assumes today’s utilization holds flat, your projection is wrong.
A workable approach: take your covered adult population, apply your proposed eligibility criteria against your own biometric and diagnosis data rather than national averages, and then build three uptake scenarios instead of one. A conservative case, an expected case, and a case where uptake runs well above plan. Price each GLP-1 coverage scenario against your net cost per fill and see which ones your budget survives. Employers that skipped this step in 2024 and 2025 are the ones now facing coverage reversals they never intended to make, and reversing GLP-1 coverage is far more damaging to trust than declining to add it in the first place.
2. Persistence, not enrollment
This is the number almost nobody models correctly, and it cuts both ways.
A cohort study of more than 125,000 patients starting GLP-1 receptor agonists found that 64.8 percent of patients without type 2 diabetes discontinued within one year, compared with 46.5 percent of those with diabetes. The Employee Benefit Research Institute’s analysis of GLP-1 impacts on employer plan premiums cites similar patterns, noting that high discontinuation reduces utilization while also undercutting the clinical case, since patients who stop typically regain weight and see cardiovascular improvements regress toward baseline.
Read that carefully, because it is uncomfortable. High discontinuation lowers your near-term spend. It also means a large share of what you spent bought very little durable health benefit. A GLP-1 coverage strategy that ignores persistence is buying starts, not outcomes.
3. Net cost per member, not list price
List price is theater. What matters is your net cost after rebates, and whether those rebates actually reach your plan or get absorbed somewhere in the supply chain. Employers in Peterson-KFF focus groups repeatedly cited deteriorating rebate economics as a reason for dropping weight-loss coverage entirely.
If you cannot get a clean answer on net cost per fill from your current arrangement, that is not a GLP-1 coverage problem. That is a contract problem, and it is affecting far more than one drug class.
Four GLP-1 Coverage Designs Employers Are Using for 2027
The market has settled into roughly four approaches. None of them is universally right. What matters is whether you can explain why you chose yours.
- Full exclusion for weight management. Cover GLP-1s for diabetes and other approved indications, exclude weight loss. Clean, predictable, and increasingly common. The tradeoff is real: you are declining a therapy your employees want and can see other plans covering.
- Clinical gating. Keep GLP-1 coverage but require objective biometric eligibility, prior authorization, documented participation in a lifestyle or weight-management program, and continuation criteria tied to measured progress. This is the most defensible middle path when it is administered honestly rather than used as a soft denial mechanism.
- Cost-share redesign. Maintain access, move GLP-1s to a dedicated tier with higher member cost share or a defined annual maximum. Preserves choice while capping plan exposure. Watch the equity impact, since affordability barriers fall hardest on the employees most likely to benefit.
- Carve-out to a specialized administrator. Move the category to a transparent pharmacy arrangement with pass-through pricing and full claims visibility. This is where a pharmacy benefits administrator model tends to outperform a traditional PBM relationship, because you can actually see what you are paying and hold someone accountable for it.
The Fiduciary Question Underneath the Cost Question
Here is what gets lost when GLP-1 coverage becomes purely a budget conversation.
You are a plan fiduciary. That obligation does not require you to cover every drug your employees want, and it does not require you to cut costs at any expense. It requires you to make prudent, documented decisions in the interest of your participants, using real data, with a process you could explain to a regulator or a plaintiff’s attorney.
A defensible GLP-1 coverage decision has four pieces. You analyzed your own claims and eligible population rather than borrowing someone else’s benchmark. You evaluated more than one design. You understood what your plan actually pays net of rebates. And you wrote down why you chose what you chose.
An indefensible decision looks like this: your broker told you what the market is doing, you approved it, and there is no record of the analysis. That is the status quo, and it has been costing employers money and credibility for years.
There is a second obligation that rarely makes the agenda, and it is the one employees actually feel. However you land on GLP-1 coverage, your people need to understand the rule before they need to use it. Ambiguous plan language, prior authorization criteria nobody can find, and appeals processes that function as attrition all create the same outcome: employees give up on care they were technically entitled to. If your design includes clinical gating, publish the criteria in plain language, tell people exactly what documentation they need, and make sure your service team can walk someone through it. A benefit your employees cannot navigate is not a benefit. It is a line item with good intentions attached.
72%Of large employers covering GLP-1s for weight management, the share that expect to keep that coverage in 2027. Ten percent expect to drop it (Business Group on Health, 2026).
How to Work Your GLP-1 Coverage Decision Before Renewal
If your plan year starts January 1, you have weeks, not months. A workable sequence:
- Pull two years of pharmacy claims segmented by indication, not just drug name. Diabetes, weight management, and other approved indications behave differently and should be decided separately.
- Measure your actual persistence. What percentage of members who started a GLP-1 last year are still filling at month twelve? That single number reframes the entire ROI conversation.
- Get your net cost per fill in writing. If your vendor cannot or will not produce it, you have learned something more important than the number.
- Model three designs, not one. Price out full exclusion, clinical gating, and a carve-out against your own population.
- Decide on communication before you decide on coverage. If you are narrowing GLP-1 coverage, employees deserve to hear it from you, early, with the reasoning and the alternatives you are offering instead.
- Document the process. Minutes, data reviewed, options considered, rationale. This is the part everyone skips and the part that protects you.
The Bottom Line on GLP-1 Coverage for 2027
These drugs are not a passing trend and they are not a budget line you can quietly delete. They work for many people, they cost a great deal, and the market around them is moving fast enough that a decision made on 2025 assumptions is already out of date.
The employers handling this well are not the ones who found a clever loophole. They are the ones who stopped treating GLP-1 coverage as a yes-or-no vote and started treating it as a design problem with real data behind it. That is harder work. It is also the only version of this decision you can stand behind twelve months from now.
You have run every other part of your business on strategy. Your pharmacy benefit deserves the same.
GLP-1 Coverage: Frequently Asked Questions
Are employers required to cover GLP-1 medications?
No. There is no federal mandate requiring employer-sponsored plans to cover GLP-1s for weight management, and anti-obesity medications are commonly excluded. What is required is that whatever you decide gets applied consistently, documented properly, and disclosed accurately in your plan documents. Some state insurance mandates apply to fully insured plans, so confirm your specific situation with counsel.
Can we cover GLP-1s for diabetes but exclude them for weight loss?
Yes, and it is the most common structure in the market. IFEBP found 60 percent of employers cover GLP-1s for diabetes only, while 36 percent cover both diabetes and weight management. Just be precise in your plan language about which indications qualify, because the same molecule now carries approvals for diabetes, weight management, sleep apnea, and cardiovascular risk reduction. Vague drafting is how exclusions get overturned on appeal.
Does the Medicare GLP-1 Bridge change anything for our plan?
Not directly. The Bridge sits outside Part D and does not touch commercial plans. What it changes is the conversation, because it puts a federally negotiated price of $245 per monthly supply into public view. Expect employees and finance leaders to ask why your plan pays more, and have an answer ready.
What BMI threshold do most employers use for GLP-1 coverage?
Practice is genuinely split. Among employers that apply a minimum BMI, IFEBP found 38 percent set it at exactly 30, 37 percent use a threshold below 30, and 25 percent require above 30. Most pair the BMI criterion with comorbidity requirements and documented participation in a lifestyle program, since BMI alone is a blunt eligibility screen.
Will cheaper list prices and oral GLP-1s lower our 2027 spend?
Probably not on their own. Lower per-unit pricing helps, but oral formulations remove a barrier for people who will not use an injectable, and most large employers expect demand to rise as a result. Total spend is unit price multiplied by utilization, and utilization is the variable moving fastest. Model both.
How much notice do we owe employees if we drop GLP-1 coverage?
Under ERISA, a material reduction in covered services or benefits generally requires a Summary of Material Modifications furnished within 60 days of adopting the change. Practically, give more notice than the minimum. People who are mid-treatment need time to plan, and a transition runway with clear alternatives is the difference between a hard decision and a morale event.
Ready to build a GLP-1 strategy you can defend?
Ethos Benefits works as a fiduciary advisor on a transparent, flat-fee model. We start with your claims data, not a market benchmark, and we show you exactly what your plan is paying and why.
Schedule your Strategic Analysis and let’s look at your numbers together.
This article is provided for general informational purposes and does not constitute legal, tax, medical, or clinical advice. Coverage decisions should be reviewed with qualified counsel and clinical advisors based on your plan’s specific circumstances. Data reflects publicly available research as of publication.
